B
Bull
Bull · 25%NAMS
$42.47
Scenario price
$19.830
-0.759 (-3.83%)At close
Loading chart…
- High
- 20.665
- Open
- 20.510
- VWAP
- 20.07
- Volume
- 1.94M
- Mkt Cap
- 1.76B
- Low
- 19.710
- Amount
- 38.88M
- EV/EBITDA, TTM
- -0.90
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
AI analysis of NewAmsterdam Pharma Company NV (NAMS)
SellNewAmsterdam Pharma is not a good buy right now due to significant financial losses and negative market sentiment. The stock is currently priced at $19.83, down 43.66% year-to-date, and has an RSI of 25.93, indicating it is oversold. The company reported a net loss of $64.1 million in Q2 2026, a substantial increase from previous losses, which raises concerns about its financial health and market competitiveness. Additionally, insider selling has increased by 113.69%, suggesting a lack of confidence from those closest to the company. The main risk is the forward P/E ratio of 119.05, indicating high valuation expectations that may not be met given the current financial performance.
Valuation Metrics
The current forward P/E ratio for NewAmsterdam Pharma Company NV (NAMS) is 119.05, compared to its 5-year average forward P/E of 5.15.
Alphio AI Price Scenarios for NAMS
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding NAMS
Events Timeline
News
9.009-23PRnewswireMenarini and NewAmsterdam Receive EU Approval for New Drugs
8.509-22PRnewswireObicetrapib Receives First EU Market Approval for LDL-C Treatment
8.509-21PRnewswireObicetrapib Receives First-in-Class Approval
8.509-21PRnewswireNewAmsterdam and Menarini Achieve First Global Approval for Obicetrapib
8.509-21NewsfilterNewAmsterdam and Menarini Achieve First Global Approval for Obicetrapib
NAMS FAQ — answered by Alphio AI
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
NewAmsterdam Pharma is not a good buy right now due to significant financial losses and negative market sentiment. The stock is currently priced at $19.83, down 43.66% year-to-date, and has an RSI of 25.93, indicating it is oversold. The company reported a net loss of $64.1 million in Q2 2026, a substantial increase from previous losses, which raises concerns about its financial health and market competitiveness. Additionally, insider selling has increased by 113.69%, suggesting a lack of confidence from those closest to the company. The main risk is the forward P/E ratio of 119.05, indicating high valuation expectations that may not be met given the current financial performance.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.